Abstract: This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and/or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

Abstract: This description provides novel strategies and methods for treatment of hyperproliferation conditions such as keloids, lung fibrosis, and lung cancer with the use of bi-functional molecules that target growth factors. A bifunctional hepatoma-derived growth factor (HDGF)-specific antibody for these methods comprises at least one complementarity determining region (CDR) specific for HDGF, at least one receptor domain that specifically binds to a growth factor selected from vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF?).

Abstract: This description provides novel strategies and methods for treatment of hyperproliferation conditions such as keloids, lung fibrosis, and lung cancer with the use of bi-functional molecules that target growth factors. A bifunctional hepatoma-derived growth factor (HDGF)-specific antibody for these methods comprises at least one complementarity determining region (CDR) specific for HDGF, at least one receptor domain that specifically binds to a growth factor selected from vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF?).

Abstract: The present invention provides methods of cancer therapy or diagnosis involving targeting hepatoma-derived growth factor (HDGF). In certain embodiments, an antibody and/or siRNA may be used to inhibit HDGF, optionally coupled to or combined with other cancer therapies.

Abstract: Cancer screening models based on analysis of mass spectroscopy data can be used to predict upper aerodigestive tract cancer, including lung and head and neck cancers. Models can be generated by comparing spectral weight values obtained from upper aerodigestive tract cancer patients and from patients at high risk for such cancer. Predictor or covariate values identify spectral weight values associated with upper aerodigestive tract cancer.